RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.
Orr-Urtreger A, Bar-Shira A, Bercovich D, Matarasso N, Rozovsky U, Rosner S, Soloviov S, Rennert G, Kadouri L, Hubert A, Rennert H, Matzkin H.
Orr-Urtreger A, et al. Among authors: bercovich d.
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):474-9. doi: 10.1158/1055-9965.EPI-05-0606.
Cancer Epidemiol Biomarkers Prev. 2006.
PMID: 16537704
We estimated that the RNASEL 471delAAAG founder mutation, which was detected in 2% of the Ashkenazi Jews, originated between the 2nd and 5th centuries A.D., compared with the less frequent (1%) BRCA1 185delAG founder mutation, which originated hundreds of years earlier. .. …
We estimated that the RNASEL 471delAAAG founder mutation, which was detected in 2% of the Ashkenazi Jews, originated between the 2nd and 5th …